VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

BioAtla, Inc. (BCAB) Total Return Calculator with Dividends Reinvested

BioAtla, Inc.

Popular:

The total return for BioAtla, Inc. (BCAB) stock is -80.58% over the past 12 months. So far it's down 83.71% this year. The 5-year total return is -99.81%, meaning $10,000 invested in BCAB stock 5 years ago would be worth $19 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in BCAB 1 year ago, it would be worth $1,942 today — you'd have lost $8,058.

With Dividends Reinvested$1,942-80.58%

Price Only (No DRIP)$1,942-80.58%

Period2025-05-07 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in BCAB

1Y$1,942-$8,058 (-80.6%)-80.6% CAGR

3Y$267-$9,733 (-97.3%)-70.1% CAGR

5Y$19-$9,981 (-99.8%)-71.6% CAGR

10Y$28-$9,972 (-99.7%)-44.4% CAGR

15Y$28-$9,972 (-99.7%)-32.4% CAGR

20Y$28-$9,972 (-99.7%)-25.5% CAGR

30Y$28-$9,972 (-99.7%)-17.8% CAGR

BioAtla, Inc. did not pay dividends during this period. Total return = price return.

Loading BCAB total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-83.71%	—	-83.71%	—	$1,629
1Y	-80.58%	-80.58%	-80.58%	—	$1,942
3Y	-97.33%	-70.12%	-97.33%	—	$267
5Y	-99.81%	-71.56%	-99.81%	—	$19
10Y	-99.72%	-44.44%	-99.72%	—	$28
15Y	-99.72%	-32.41%	-99.72%	—	$28
20Y	-99.72%	-25.46%	-99.72%	—	$28
30Y	-99.72%	-17.79%	-99.72%	—	$28

Risk & Highlights

Best Year+9.64%2020

Worst Year-77.69%2024

Max Drawdown-99.42%2025-11-18 → 2026-01-24

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-53.67%	-53.67%	—	+0.41%	-54.1pp
2025	-7.49%	-7.49%	—	+16.64%	-24.1pp
2024	-77.69%	-77.69%	—	+24.00%	-101.7pp
2023	-69.55%	-69.55%	—	+24.81%	-94.4pp
2022	-56.07%	-56.07%	—	-19.95%	-36.1pp

BCAB underperformed the S&P 500 by 110.95pp over the past year (-80.58% vs +30.37%).

Loading summary...

BCAB Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
BCABBioAtla, Inc.	$5M	-6.7%	-83.7%	-80.6%	—	-97.3%	-99.8%	-99.7%
IMVTImmunovant, Inc.	$5.5B	+10.6%	+5.1%	+96.1%	—	+40.9%	+62.4%	+173.6%
RCUSArcus Biosciences, Inc.	$2.5B	+12.3%	+6.5%	+209.6%	—	+24.9%	-18.6%	+45.9%
AGENAgenus Inc.	$132M	-7.6%	+16.1%	+27.1%	—	-88.2%	-93.9%	-94.3%
MGNXMacroGenics, Inc.	$186M	-12.2%	+82.6%	+97.3%	—	-59.4%	-90.8%	-84.4%
FATEFate Therapeutics, Inc.	$280M	+111.3%	+145.5%	+143.0%	—	-55.4%	-96.8%	+40.5%
MIRMMirum Pharmaceuticals, Inc.	$5.2B	+7.6%	+31.8%	+149.7%	—	+290.5%	+451.3%	+679.2%
ARVNArvinas, Inc.	$652M	-10.4%	-11.2%	+52.8%	—	-58.7%	-84.0%	-36.5%
NKTRNektar Therapeutics	$1.6B	+9.4%	+92.0%	+818.2%	—	+621.8%	-72.3%	-59.1%
AGIOAgios Pharmaceuticals, Inc.	$1.6B	-21.6%	+1.3%	-2.4%	—	+8.3%	-50.7%	-42.2%
REGNRegeneron Pharmaceuticals, Inc.	$73.7B	-6.7%	-8.5%	+27.1%	+0.6pp	-5.1%	+43.6%	+90.0%

Compare:BCAB vs IMVT BCAB vs RCUS BCAB vs AGEN BCAB vs IMVT vs RCUS

About BCAB Dividend Returns

BioAtla, Inc. (BCAB) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of BCAB over the past year?

BioAtla, Inc. (BCAB) delivered a return of -80.58% over the past year. Since BCAB does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in BCAB be worth today?

A $10,000 investment in BioAtla, Inc. one year ago would be worth $1,942 today, representing a loss of $8,058.

Q3Does BCAB pay dividends?

BioAtla, Inc. (BCAB) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For BCAB, the total return equals the price-only return.

Q4Did BCAB beat the S&P 500?

No, BioAtla, Inc. (BCAB) underperformed the S&P 500 by 110.95 percentage points over the past year. BCAB delivered a total return of -80.58%, compared to the S&P 500's 30.37%. This means a passive S&P 500 index fund outperformed BCAB by 110.95pp during this period.

Q5What is BCAB's worst drawdown?

BioAtla, Inc. (BCAB) experienced a maximum drawdown of -99.42% over the past year, declining from its peak on 2025-11-18 to its trough on 2026-01-24. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is BCAB's long-term total return over 10, 20, or 30 years?

Here are BioAtla, Inc. (BCAB)'s long-term returns with dividends reinvested. Over 10 years, the total return is -99.7% (-44.4% CAGR) — $10,000 would have grown to $28. Over 20 years: -99.7% total return (-25.5% CAGR) — $10,000 → $28. Over 30 years: -99.7% total return (-17.8% CAGR) — $10,000 → $28. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was BCAB's best and worst year?

BioAtla, Inc.'s best calendar year was 2020 with a total return of 9.6%. Its worst year was 2024 with a total return of -77.7%. This range shows the volatility investors should expect — the difference between the best and worst year is 87.3 percentage points.